tiprankstipranks
Sino Biopharmaceutical Ltd (CH:SMZ1)
:SMZ1

Sino Biopharmaceutical (SMZ1) Price & Analysis

0 Followers

SMZ1 Stock Chart & Stats

Currently, no data available
Please return soon. This page is being updated.

Bulls Say, Bears Say

Bulls Say
High Gross MarginsConsistently very high gross margins (~78%–83%) reflect durable product-level pricing power and a specialty-biased mix. Such margins provide structural buffer to absorb SG&A/R&D spending, sustain operating profitability, and support reinvestment or licensing even if top-line growth moderates.
Improving Revenue MomentumRe-acceleration of revenue in 2025 signals strengthening commercial traction and product adoption across hospital and retail channels. Sustained top-line momentum across multiple therapeutic franchises underpins long-term scale, enabling fixed-cost leverage and funding for pipeline development.
Strong Cash GenerationImproved operating and free cash flow with a FCF-to-net-income ratio near 0.82 indicates high earnings quality and cash conversion. Reliable cash generation supports R&D, licensing deals, debt servicing, and shareholder returns without immediate dilution, strengthening financial resilience.
Bears Say
Falling Net MarginsMaterial decline and volatility in net margins reduce confidence in earnings durability and free cash flow sustainability. Persistent margin pressure limits internal funding for R&D and commercialization, and raises reliance on external financing if costs or pricing headwinds persist.
Rising LeverageA notable increase in leverage year-over-year weakens the balance sheet cushion and raises interest and refinancing risks. Higher debt levels constrain strategic optionality for M&A or large R&D investments and increase vulnerability if earnings or cash flow dip.
Dependence On Reimbursement PolicySignificant exposure to China reimbursement and centralized procurement creates structural pricing and volume risk. Policy decisions can rapidly alter access and margins for hospital-sold drugs, making revenue and profit sensitive to regulatory shifts beyond company control.

Sino Biopharmaceutical News

SMZ1 FAQ

What was Sino Biopharmaceutical Ltd’s price range in the past 12 months?
Currently, no data Available
What is Sino Biopharmaceutical Ltd’s market cap?
Sino Biopharmaceutical Ltd’s market cap is CHF8.50B.
    When is Sino Biopharmaceutical Ltd’s upcoming earnings report date?
    Sino Biopharmaceutical Ltd’s upcoming earnings report date is Aug 26, 2026 which is in 71 days.
      How were Sino Biopharmaceutical Ltd’s earnings last quarter?
      Sino Biopharmaceutical Ltd released its earnings results on Mar 26, 2026. The company reported CHF0.001 earnings per share for the quarter, missing the consensus estimate of CHF0.007 by -CHF0.006.
        Is Sino Biopharmaceutical Ltd overvalued?
        According to Wall Street analysts Sino Biopharmaceutical Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Sino Biopharmaceutical Ltd pay dividends?
          Sino Biopharmaceutical Ltd does not currently pay dividends.
          What is Sino Biopharmaceutical Ltd’s EPS estimate?
          Sino Biopharmaceutical Ltd’s EPS estimate is 0.01.
            How many shares outstanding does Sino Biopharmaceutical Ltd have?
            Sino Biopharmaceutical Ltd has 18,705,018,000 shares outstanding.
              What happened to Sino Biopharmaceutical Ltd’s price movement after its last earnings report?
              Sino Biopharmaceutical Ltd reported an EPS of CHF0.001 in its last earnings report, missing expectations of CHF0.007. Following the earnings report the stock price went same N/A.
                Which hedge fund is a major shareholder of Sino Biopharmaceutical Ltd?
                Currently, no hedge funds are holding shares in CH:SMZ1
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  Sino Biopharmaceutical Ltd

                  Established in 2000 and headquartered in Wan Chai, Hong Kong, Sino Biopharmaceutical Limited functions as an investment holding entity overseeing a prominent research and development-focused pharmaceutical conglomerate. Its core operations are primarily situated within the People's Republic of China, segmented into three main areas: modern and traditional Chinese medicines and chemical pharmaceuticals, investment ventures, and other diverse activities. The company maintains an extensive portfolio of pharmaceutical products addressing numerous therapeutic categories. This includes oncology treatments such as Qingkeshu tablets and Anxian capsules; cardiovascular and cerebrovascular medications like Kaina and Anrixin tablets; hepatitis remedies, including Tianqingganmei injections; and orthopedic solutions such as Gaisanchun capsules. The product range also covers respiratory system drugs, parenteral nutritional therapies (e.g., Xinhaineng injections), and other miscellaneous medicines like Tuotuo tablets. Furthermore, Sino Biopharmaceutical distributes a selection of advanced pharmaceuticals, including Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. Beyond pharmaceutical manufacturing and distribution, the company engages in a broad array of healthcare-related services and investments. These activities encompass managing property assets, retailing and distributing pharmaceutical goods, offering optometry services and selling ophthalmic products, and operating hospitals. It also provides medical management and health information consultancy, bio-tech transfer and advisory services, and manufactures and markets health food products. Additionally, the company performs orthopedic outpatient and surgical procedures, develops medical and health technologies, trades optical glasses, and conducts research, development, and sales of medical devices and active pharmaceutical ingredients.

                  Sino Biopharmaceutical (SMZ1) Earnings & Revenues

                  SMZ1 Stock 12 Month Forecast

                  Average Price Target

                  CHF0.86
                  eyJuYXZpZ2F0b3IiOnsiZGlzYWJsZWQiOnRydWV9LCJleHBvcnRpbmciOnsiZW5hYmxlZCI6ZmFsc2V9LCJ0aXRsZSI6eyJ0ZXh0IjpudWxsfSwiY2hhcnQiOnsiaGVpZ2h0IjoyMDAsInN0eWxlIjp7ImZvbnRGYW1pbHkiOiJSb2JvdG8gRmxleCwgLWFwcGxlLXN5c3RlbSwgQmxpbmtNYWNTeXN0ZW1Gb250LCBTZWdvZSBVSSwgUm9ib3RvLCBIZWx2ZXRpY2EsIEFyaWFsLCBzYW5zLXNlcmlmLCBBcHBsZSBDb2xvciBFbW9qaSwgU2Vnb2UgVUkgRW1vamksIFNlZ29lIFVJIFN5bWJvbCIsImZvbnRXZWlnaHQiOiI0MDAiLCJjb2xvciI6IiM1ZDVkNWUifX0sInlBeGlzIjp7ImxhYmVscyI6eyJzdHlsZSI6eyJjb2xvciI6ImluaGVyaXQifX0sInZpc2libGUiOmZhbHNlfSwicGxvdE9wdGlvbnMiOnsic2VyaWVzIjp7InN0YXRlcyI6eyJpbmFjdGl2ZSI6eyJvcGFjaXR5IjoxfX19fSwieEF4aXMiOnsibGFiZWxzIjp7InN0eWxlIjp7ImNvbG9yIjoiaW5oZXJpdCJ9fSwidmlzaWJsZSI6ZmFsc2V9LCJsZWdlbmQiOnsic3ltYm9sUmFkaXVzIjowLCJzeW1ib2xQYWRkaW5nIjo0LCJzeW1ib2xIZWlnaHQiOjE0LCJib3JkZXJXaWR0aCI6MCwic3ltYm9sV2lkdGgiOjE0LCJhbGlnbiI6ImxlZnQiLCJ2ZXJ0aWNhbEFsaWduIjoiYm90dG9tIiwiZW5hYmxlZCI6ZmFsc2V9LCJ0b29sdGlwIjp7ImJhY2tncm91bmRDb2xvciI6IndoaXRlIn0sImNyZWRpdHMiOnsiZW5hYmxlZCI6ZmFsc2V9LCJhY2Nlc3NpYmlsaXR5Ijp7ImRlc2NyaXB0aW9uIjoiIn0sInNlcmllcyI6W3sidHlwZSI6ImFyZWEiLCJkYXRhIjpbXX1dfQ==
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Innovent Biologics
                  3SBio
                  Akeso, Inc.
                  Shanghai Junshi Biosciences Co., Ltd. Class H
                  Shanghai Henlius Biotech, Inc. Class H

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks